Effect of PARP Inhibitors on Glomerular Filtration Rate
NCT04367467 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 2
Last updated 2022-01-26
Summary
The purpose of this study is to observe whether PARP inhibitors have an effect on serum creatinine level, and whether this reflects a change in creatinine secretion or a true change in kidney function.
Conditions
Interventions
- OTHER
-
Kidney Function Test
Cystatin-C measurement
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Payal Shah, MD · University of Pennsylvania
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-02-03
- Primary Completion
- 2021-07-01
- Completion
- 2021-07-01
Countries
- United States
Study Locations
More Related Trials
-
A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma
NCT00523640 ·Status: TERMINATED ·Phase: PHASE2
-
Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib
NCT05263609 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
NCT06447662 ·Status: RECRUITING ·Phase: PHASE1
-
Study of RP-6306 With Gemcitabine in Advanced Solid Tumors
NCT05147272 ·Status: TERMINATED ·Phase: PHASE1
-
Avelumab, Palbociclib and Axitinib in Advanced RCC
NCT05176288 ·Status: WITHDRAWN ·Phase: PHASE2
-
Neoadjuvant Chemotherapy Plus Nephroureterectomy for Locally Advanced Upper Tract Transitional Cell Cancer
NCT00696007 ·Status: WITHDRAWN ·Phase: PHASE2
-
Pemetrexed Plus Gemcitabine in Renal Cell Cancer
NCT00491075 ·Status: TERMINATED ·Phase: PHASE2
-
A Safety and Dose-finding Study of JNJ-38877605 in Patients With Advanced or Refractory Solid Tumors.
NCT00651365 ·Status: TERMINATED ·Phase: PHASE1
-
INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
NCT03920839 ·Status: WITHDRAWN ·Phase: PHASE1
-
Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors
NCT00074321 ·Status: COMPLETED ·Phase: PHASE1
-
Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer
NCT04337970 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
NCT02769962 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase II Trial of Gemcitabine and Oxaliplatin for Triple Negative Metastatic Breast Cancer
NCT00674206 ·Status: TERMINATED ·Phase: PHASE2
-
Oxaliplatin, Gemcitabine, and Erlotinib Study in Patients With Advanced Chemo-naïve Pancreatic Cancer
NCT00636883 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
NCT01012362 ·Status: TERMINATED ·Phase: PHASE1
-
Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem
NCT00612677 ·Status: TERMINATED ·Phase: PHASE2
-
Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma
NCT00705874 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Chemotherapy In Treating Patients With Metastatic or Unresectable Solid Tumors
NCT00005068 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
NCT01235962 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)
NCT02014636 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
NCT06441747 ·Status: RECRUITING ·Phase: PHASE2
-
Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer
NCT00401128 ·Status: COMPLETED ·Phase: PHASE2
-
Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors
NCT00047047 ·Status: COMPLETED ·Phase: PHASE1
-
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
NCT02582697 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
NCT06704724 ·Status: TERMINATED ·Phase: PHASE1